Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.64+0.02 (+0.19%)
Close on Nov 13, 2026Market cap $895.05MP/E –Yield –
Corvus Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Corvus Pharmaceuticals's cash was $202.90M at Sep 30, 2026. For fiscal 2025 it was $56.80M, up 9.2% from the year before. Over ten years it grew 30.0% a year on average. The highest annual figure on record is $134.90M in fiscal 2016.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.80M | +9.2% |
| FY2024 | Dec 31, 2024 | $52.00M | +91.9% |
| FY2023 | Dec 31, 2023 | $27.10M | -35.9% |
| FY2022 | Dec 31, 2022 | $42.30M | -39.1% |
| FY2021 | Dec 31, 2021 | $69.50M | +56.9% |
| FY2020 | Dec 31, 2020 | $44.30M | -43.2% |
| FY2019 | Dec 31, 2019 | $78.00M | -31.9% |
| FY2018 | Dec 31, 2018 | $114.60M | +27.2% |
| FY2017 | Dec 31, 2017 | $90.10M | -33.2% |
| FY2016 | Dec 31, 2016 | $134.90M | +3186.2% |
| FY2015 | Dec 31, 2015 | $4.11M | -67.2% |
| FY2014 | Dec 31, 2014 | $12.52M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $202.90M | +208.8% |
| Q2 FY2026 | Jun 30, 2026 | $215.20M | +189.2% |
| Q1 FY2026 | Mar 31, 2026 | $236.70M | +435.5% |
| Q4 FY2025 | Dec 31, 2025 | $56.80M | +9.2% |
| Q3 FY2025 | Sep 30, 2025 | $65.70M | +57.6% |
| Q2 FY2025 | Jun 30, 2025 | $74.40M | +57.6% |
| Q1 FY2025 | Mar 31, 2025 | $44.20M | +100.0% |
| Q4 FY2024 | Dec 31, 2024 | $52.00M | +91.9% |
| Q3 FY2024 | Sep 30, 2024 | $41.70M | +29.5% |
| Q2 FY2024 | Jun 30, 2024 | $47.20M | +27.6% |
| Q1 FY2024 | Mar 31, 2024 | $22.10M | -35.9% |
| Q4 FY2023 | Dec 31, 2023 | $27.10M | -35.9% |
| Q3 FY2023 | Sep 30, 2023 | $32.20M | -35.1% |
| Q2 FY2023 | Jun 30, 2023 | $37.00M | -34.7% |
| Q1 FY2023 | Mar 31, 2023 | $34.50M | -45.2% |
| Q4 FY2022 | Dec 31, 2022 | $42.30M | -39.1% |
| Q3 FY2022 | Sep 30, 2022 | $49.60M | -35.0% |
| Q2 FY2022 | Jun 30, 2022 | $56.70M | -14.7% |
| Q1 FY2022 | Mar 31, 2022 | $62.90M | -7.5% |
| Q4 FY2021 | Dec 31, 2021 | $69.50M | +56.9% |
| Q3 FY2021 | Sep 30, 2021 | $76.30M | +48.4% |
| Q2 FY2021 | Jun 30, 2021 | $66.50M | +12.1% |
| Q1 FY2021 | Mar 31, 2021 | $68.00M | -1.0% |
| Q4 FY2020 | Dec 31, 2020 | $44.30M | -43.2% |
| Q3 FY2020 | Sep 30, 2020 | $51.40M | -40.5% |
| Q2 FY2020 | Jun 30, 2020 | $59.30M | -38.7% |
| Q1 FY2020 | Mar 31, 2020 | $68.70M | -35.1% |
| Q4 FY2019 | Dec 31, 2019 | $78.00M | -31.9% |
| Q3 FY2019 | Sep 30, 2019 | $86.40M | -29.5% |
| Q2 FY2019 | Jun 30, 2019 | $96.80M | -27.3% |
| Q1 FY2019 | Mar 31, 2019 | $105.80M | -26.5% |
| Q4 FY2018 | Dec 31, 2018 | $114.60M | +27.2% |
| Q3 FY2018 | Sep 30, 2018 | $122.60M | +23.0% |
| Q2 FY2018 | Jun 30, 2018 | $133.20M | +20.8% |
| Q1 FY2018 | Mar 31, 2018 | $143.90M | +17.9% |
| Q4 FY2017 | Dec 31, 2017 | $90.10M | -33.2% |
| Q3 FY2017 | Sep 30, 2017 | $99.70M | – |
| Q2 FY2017 | Jun 30, 2017 | $110.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $122.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $134.90M | – |
See a number that looks wrong?